Access the full text.
Sign up today, get DeepDyve free for 14 days.
Jing Liu, W. Kuo, T. Seiwert, M. Lingen, Mark Ciaccio, Richard Jones, M. Rosner, Ezra Cohen (2011)Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin
Head & Neck, 33
T. Shimamura, H. Greulich, F. Solca, Kwok-kin Wong (2007)C7-04: Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model
Journal of Thoracic Oncology, 2
B. Burtness, M. Goldwasser, W. Flood, B. Mattar, A. Forastiere (2005)Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 34
(1997)Expression of c-erbB proto-oncogene family member in squamous cell carcinoma of the head and neck
E. Tzahar, H. Waterman, Xiomei Chen, G. Levkowitz, D. Karunagaran, S. Lavi, B. Ratzkin, Y. Yarden (1996)A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
Molecular and Cellular Biology, 16
L. Zhang, Carla Castanaro, Bo Luan, Katie Yang, Lian Fan, J. Fairhurst, A. Rafique, Terra Potocky, Jing Shan, F. Delfino, Ergang Shi, Tammy Huang, Joel Martin, Gang Chen, D. MacDonald, J. Rudge, G. Thurston, C. Daly (2014)ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Molecular Cancer Therapeutics, 13
J. Grève, E. Teugels, C. Geers, L. Decoster, D. Galdermans, J. Mey, H. Everaert, I. Umelo, P. Veld, D. Schallier (2012)Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
Lung cancer, 76 1
S. Khelwatty, S. Essapen, A. Seddon, H. Modjtahedi (2011)Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
International journal of oncology, 39 2
J. Grandis, D. Tweardy (1993)Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.
Cancer research, 53 15
J. Vermorken, R. Mesía, F. Rivera, É. Remenár, A. Kawecki, S. Rottey, J. Erfán, D. Zabolotnyy, H. Kienzer, D. Cupissol, F. Peyrade, M. Benasso, I. Vynnychenko, D. Raucourt, C. Bokemeyer, A. Schueler, N. Amellal, R. Hitt (2008)Platinum-based chemotherapy plus cetuximab in head and neck cancer.
The New England journal of medicine, 359 11
(1991)Comparative investigation of cerbB2/neu expression in head and neck tumors andmammary cancer
(1999)Epidermal growth factor receptor blockage with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
E. Cohen, F. Rosen, W. Stadler, W. Recant, K. Stenson, D. Huo, E. Vokes (2003)Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 10
J. Baselga, J. Trigo, J. Bourhis, J. Tortochaux, H. Cortés-Funes, R. Hitt, P. Gascón, N. Amellal, A. Harstrick, A. Eckardt (2005)Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 24
(2007)Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model
N. Young, Jing Liu, C. Pierce, T. Wei, T. Grushko, O. Olopade, Wanqing Liu, Christine Shen, T. Seiwert, E. Cohen (2013)Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition
Molecular Oncology, 7
Daizong Li, L. Ambrogio, L. Ambrogio, T. Shimamura, S. Kubo, Masaya Takahashi, L. Chirieac, R. Padera, G. Shapiro, A. Baum, F. Himmelsbach, W. Rettig, M. Meyerson, M. Meyerson, F. Solca, H. Greulich, H. Greulich, Kwok-kin Wong (2008)BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
T. Seiwert, J. Fayette, D. Cupissol, J. Campo, P. Clement, R. Hitt, M. Degardin, W. Zhang, A. Blackman, E. Ehrnrooth, E. Cohen (2014)A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†
Annals of Oncology, 25
Nicolas Magné, J. Fischel, A. Dubreuil, P. Formento, M. Poupon, Pierre Laurent-Puig, Gérard Milano (2002)Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)
British Journal of Cancer, 86
L. Klapper, Stefanie Glathe, N. Vaisman, N. Hynes, G. Andrews, M. Sela, Y. Yarden (1999)The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.
Proceedings of the National Academy of Sciences of the United States of America, 96 9
N. Hynes, H. Lane (2005)ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors
Nature Reviews Cancer, 5
A. Wakeling, S. Guy, J. Woodburn, S. Ashton, B. Curry, A. Barker, K. Gibson (2002)ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
Cancer research, 62 20
T. Yap, L. Vidal, J. Adam, P. Stephens, J. Spicer, H. Shaw, J. Ang, G. Temple, S. Bell, M. Shahidi, M. Uttenreuther-Fischer, P. Stopfer, A. Futreal, H. Calvert, J. Bono, R. Plummer (2010)Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 25
(2005)ERBB receptors and cancer: the complexity of targeted inhibitors
Nat Rev Cancer, 5
V. Pollack, D. Savage, Deborah Baker, Konstantinos Tsaparikos, D. Sloan, J. Moyer, E. Barbacci, L. Pustilnik, T. Smolarek, John Davis, M. Vaidya, L. Arnold, J. Doty, K. Iwata, M. Morin (1999)Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
The Journal of pharmacology and experimental therapeutics, 291 2
De Grèvea, E. Teugelsa, C. Geersa, L. Decostera, D. Galdermansb, J. Meya, H. Everaerta, I. Umeloa, In’t Velda, D. Schalliera (2012)linical activity of afatinib ( BIBW 2992 ) in patients with lung adenocarcinoma ith mutations in the kinase domain of HER 2 / neu
D. Soulières, N. Senzer, E. Vokes, M. Hidalgo, S. Agarwala, L. Siu (2004)Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 1
A. Rivière, J. Becker, T. Löning (1991)Comparative investigation of c‐erbB2/neu expression in head and neck tumors and mammary cancer
Wanqing Liu, Xiaolin Wu, Wei Zhang, R. Montenegro, D. Fackenthal, Jared Spitz, L. Huff, F. Innocenti, Soma Das, E. Cook, N. Cox, S. Bates, M. Ratain (2007)Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines
Clinical Cancer Research, 13
F. Solca, G. Dahl, A. Zoephel, G. Bader, M. Sanderson, C. Klein, O. Kraemer, F. Himmelsbach, E. Haaksma, G. Adolf (2012)Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Journal of Pharmacology and Experimental Therapeutics, 343
H. Murakami, T. Tamura, T. Takahashi, H. Nokihara, T. Naito, Y. Nakamura, K. Nishio, Y. Seki, A. Sarashina, M. Shahidi, N. Yamamoto (2012)Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
Cancer Chemotherapy and Pharmacology, 69
S. Ibrahim, E. Vasstrand, P. Liavaag, A. Johannessen, J. Lillehaug (1997)Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck.
Anticancer research, 17 6D
J. Bonner, P. Harari, J. Giralt, N. Azarnia, D. Shin, R. Cohen, Christopher Jones, R. Sur, D. Raben, J. Jassem, R. Ove, M. Kies, J. Baselga, H. Youssoufian, N. Amellal, E. Rowinsky, E. Rowinsky, K. Ang (2006)Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
The New England journal of medicine, 354 6
C. Schütze, A. Dörfler, W. Eicheler, D. Zips, S. Hering, F. Solca, M. Baumann, M. Krause (2007)Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma
Strahlentherapie und Onkologie, 183
Shyhmin Huang, J. Bock, P. Harari (1999)Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.
Cancer research, 59 8
Epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in squamous cell carcinoma of the head and neck (SCCHN). In addition to EGFR, other ErbB family members are expressed and activated in SCCHN. Afatinib is an ErbB family blocker that has been approved for treating patients with EGFR-mutated nonsmall cell lung cancer. We sought to determine the efficacy of afatinib in preclinical models and compare this to other EGFR-targeted agents. Afatinib efficacy was characterized in a panel of ten SCCHN cell lines and found to be most effective against cell lines amplified for EGFR. Afatinib had lower IC50 values than did gefitinib against the same panel. Two EGFR-amplified cell lines that are resistant to gefitinib are sensitive to afatinib. Cetuximab was not found to have a synergistic effect with afatinib either in vitro or in vivo. Both afatinib and cetuximab were effective in tumor xenograft model. Afatinib is an effective agent in SCCHN especially in models with EGFR amplification.
Targeted Oncology – Springer Journals
Published: Jan 6, 2015
Access the full text.
Sign up today, get DeepDyve free for 14 days.